APELLIS PHARMACEUTICALS INC. - COMMON STOCK
28.25
13-十一月-24 16:45:00
15 分钟延时
股票
-1.01
-3.45%
今日范围
28.23 - 29.94
ISIN
N/A
来源
NASDAQ
-
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
07 5月 2024 07:05:00 条件 Nasdaq GlobeNewswire
-
06 5月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
01 5月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
26 4月 2024 07:15:00 条件 Nasdaq GlobeNewswire
-
23 4月 2024 07:00:14 条件 Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 4月 2024 16:05:00 条件 Nasdaq GlobeNewswire
-
01 4月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
11 3月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 3月 2024 16:05:00 条件 Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
27 2月 2024 07:05:00 条件 Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
26 2月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
20 2月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 2月 2024 16:05:00 条件 Nasdaq GlobeNewswire
-
26 1月 2024 07:06:23 条件 Nasdaq GlobeNewswire
-
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
08 1月 2024 09:00:00 条件 Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 1月 2024 16:05:00 条件 Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 1月 2024 07:00:00 条件 Nasdaq GlobeNewswire
-
28 12月 2023 07:00:00 条件 Nasdaq GlobeNewswire
-
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
14 12月 2023 07:00:00 条件 Nasdaq GlobeNewswire
-
11 12月 2023 07:00:00 条件 Nasdaq GlobeNewswire